Azeliragon HCl
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 329832

CAS#: 1284150-65-7 (2HCl)

Description: Azeliragon, also known as TTP488 and PF-04494700, is a potent and orally active RAGE inhibitor. RAGE (receptor for advanced glycation endproducts) is a pattern recognition receptor, which affects the movement of amyloid, an Alzheimer's-associated protein, into the brain. In preclinical studies, azeliragon decreased brain amyloid in mice and improved their performance on behavior tests. Azeliragon is a promising agent for for Alzheimer's disease and cerebral amyloid angiopathy.


Price and Availability

Size
Price

10mg
USD 150
100mg
USD 750
1g
USD 2950
Size
Price

25mg
USD 250
200mg
USD 1250
2g
USD 4950
Size
Price

50mg
USD 450
500mg
USD 1950
5g
Ask price

Azeliragon HCl, purity > 98%, is in stock. The same day shipping out after order is received. Note: the estimated shipping out time for order > 4g may be 2 weeks.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 329832
Name: Azeliragon HCl
CAS#: 1284150-65-7 (2HCl)
Chemical Formula: C32H40Cl3N3O2
Exact Mass:
Molecular Weight: 605.041
Elemental Analysis: C, 63.52; H, 6.66; Cl, 17.58; N, 6.95; O, 5.29


Related CAS #: 1284150-65-7 (2HCl)   603148-36-3 (free base)    

Synonym: Azeliragon HCl; Azeliragon hydrochloride; Azeliragon dihydrochloride; TTP488 HCl; TTP-488; TTP 488; PF-04494700; PF 04494700; PF04494700.

IUPAC/Chemical Name: 3-(4-(2-butyl-1-(4-(4-chlorophenoxy)phenyl)-1H-imidazol-4-yl)phenoxy)-N,N-diethylpropan-1-amine dihydrochloride

InChi Key: CQAGJWKITXAOAM-UHFFFAOYSA-N

InChi Code: InChI=1S/C32H38ClN3O2.2ClH/c1-4-7-9-32-34-31(25-10-16-28(17-11-25)37-23-8-22-35(5-2)6-3)24-36(32)27-14-20-30(21-15-27)38-29-18-12-26(33)13-19-29;;/h10-21,24H,4-9,22-23H2,1-3H3;2*1H

SMILES Code: CCN(CC)CCCOC1=CC=C(C2=CN(C3=CC=C(OC4=CC=C(Cl)C=C4)C=C3)C(CCCC)=N2)C=C1.[H]Cl.[H]Cl


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Panza F, Seripa D, Solfrizzi V, Imbimbo BP, Lozupone M, Leo A, Sardone R, Gagliardi G, Lofano L, Creanza BC, Bisceglia P, Daniele A, Bellomo A, Greco A, Logroscino G. Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer's disease patients. Expert Opin Emerg Drugs. 2016 Dec;21(4):377-391. Epub 2016 Oct 6. Review. PubMed PMID: 27678025.

2: Wautier MP, Guillausseau PJ, Wautier JL. Activation of the receptor for advanced glycation end products and consequences on health. Diabetes Metab Syndr. 2016 Sep 4. pii: S1871-4021(16)30208-9. doi: 10.1016/j.dsx.2016.09.009. [Epub ahead of print] Review. PubMed PMID: 27612394.

3: Godyń J, Jończyk J, Panek D, Malawska B. Therapeutic strategies for Alzheimer's disease in clinical trials. Pharmacol Rep. 2016 Feb;68(1):127-38. doi: 10.1016/j.pharep.2015.07.006. Epub 2015 Aug 5. Review. PubMed PMID: 26721364.

4: Wautier MP, Guillausseau PJ, Wautier JL. Activation of the receptor for advanced glycation end products and consequences on health. Diabetes Metab Syndr. 2016 Sep 4. pii: S1871-4021(16)30208-9. doi: 10.1016/j.dsx.2016.09.009. [Epub ahead of print] Review. PubMed PMID: 27612394.

5: Saito S, Ihara M. New therapeutic approaches for Alzheimer's disease and cerebral amyloid angiopathy. Front Aging Neurosci. 2014 Oct 20;6:290. doi: 10.3389/fnagi.2014.00290. eCollection 2014. Review. PubMed PMID: 25368578; PubMed Central PMCID: PMC4202741.

6: Burstein AH, Grimes I, Galasko DR, Aisen PS, Sabbagh M, Mjalli AM. Effect of TTP488 in patients with mild to moderate Alzheimer's disease. BMC Neurol. 2014 Jan 15;14:12. doi: 10.1186/1471-2377-14-12. PubMed PMID: 24423155; PubMed Central PMCID: PMC4021072.

7: Chen Y, Akirav EM, Chen W, Henegariu O, Moser B, Desai D, Shen JM, Webster JC, Andrews RC, Mjalli AM, Rothlein R, Schmidt AM, Clynes R, Herold KC. RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol. 2008 Sep 15;181(6):4272-8. PubMed PMID: 18768885; PubMed Central PMCID: PMC2643976.

8: Galasko D, Bell J, Mancuso JY, Kupiec JW, Sabbagh MN, van Dyck C, Thomas RG, Aisen PS; Alzheimer's Disease Cooperative Study. Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease. Neurology. 2014 Apr 29;82(17):1536-42. doi: 10.1212/WNL.0000000000000364. Epub 2014 Apr 2. PubMed PMID: 24696507; PubMed Central PMCID: PMC4011464.

9: Sabbagh MN, Agro A, Bell J, Aisen PS, Schweizer E, Galasko D. PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease. Alzheimer Dis Assoc Disord. 2011 Jul-Sep;25(3):206-12. doi: 10.1097/WAD.0b013e318204b550. PubMed PMID: 21192237; PubMed Central PMCID: PMC3346183.